Compare AbbVie Inc (ABBV) vs Unity Software Inc (U) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Unity Software Inc — how do they compare? AbbVie Inc trades at $253.12 (market cap $449.91B), while Unity Software Inc trades at $29 (market cap $12.95B). The key difference: AbbVie Inc is far larger — about 34.7× Unity Software Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Unity Software Inc pays none. Which is the better fit depends on your goals.
| ABBV | U | |
|---|---|---|
Market Cap | $449.91B | $12.95B |
Sector | Health | Technology |
52-Week High | $261.07 | $49.47 |
52-Week Low | $184.85 | $17.13 |
Enterprise Value | $513.38B | $13.04B |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Unity Software (U) trades at $29.66, up 1.16% today, with a bullish technical outlook and strong analyst support. The stock shows improving fundamentals with revenue stable at $1.85 billion in 2025 and narrowing losses, while operating cash flow grew to $423 million. Recent news highlights Unity's strategic pivot toward AI-driven advertising and developer tools, boosting investor confidence despite ongoing net losses.
The outlook is cautiously optimistic with a consensus price target of $36.50 implying 23% upside. Key opportunities include AI integration and margin expansion, but risks persist from competitive pressures, high debt, and profitability challenges. Investors should weigh growth potential against execution risks in the evolving tech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Unity Software Inc
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC and Other Americas, of which key revenue is derived from the EMEA region. The products are used in the gaming industry, architecture and construction sector, animation industry, and designing sector.
Read more on U →
